IceCure Medical Regains Nasdaq Compliance Following Reverse Stock Split
ICCM has more than doubled off its 52-week low of $2.12 on elevated volume (4.3× avg).
Summary
IceCure Medical announced it has regained compliance with the Nasdaq minimum bid price requirement, effectively resolving the delisting threat following its recent reverse stock split.
Key Events · Corporate Governance and Compliance · ICCM
-
Regains Nasdaq Compliance
IceCure Medical received notice from Nasdaq on June 18, 2026, confirming it has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
-
Follows Reverse Stock Split
Compliance was achieved after the company's ordinary shares maintained a closing bid price of $1.00 or greater for 10 consecutive business days, from June 4 to June 17, 2026, following a 1-for-30 reverse stock split effective June 4, 2026.
-
Delisting Threat Removed
The successful regaining of compliance means the bid price deficiency matter is now closed, removing the immediate risk of delisting from Nasdaq.
Analysis · ICCM · Industrial Applications And Services
This filing confirms that IceCure Medical has successfully regained compliance with Nasdaq's minimum bid price requirement. This is a critical positive development, as it removes the immediate threat of delisting, which was a significant overhang for the company and its investors. The compliance was achieved after the previously announced 1-for-30 reverse stock split, effective June 4, 2026, boosted the share price above the $1.00 threshold for the required 10 consecutive business days.
At the time of this filing, ICCM was trading at $8.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $26.1M. The 52-week trading range was $2.12 to $42.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.